ACTIVE

UCB BIOPHARMA

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result113,8 M €+1 244,9 %over 1 year
Revenue3,6 Md €+2,3 %over 1 year
Equity1,2 Md €+6,6 %over 1 year
Workforce1 395,2 ETP+5,9 %over 1 year

Identity

Source · BCE/KBO

UCB BIOPHARMA is a Private limited company incorporated in 2013. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Anderlecht. It employs on average 1 395,2 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0543.573.053
Incorporation
24/12/2013
Legal form
Private limited company
Registered office
Allée de la Recherche 60
1070 Anderlecht · BruxellesSee on map
Contributed capital
1 017 715 816,00 €
Latest accounts
31/12/2025
Average workforce
1 395,2 ETP
Joint committees (1)
  • 207
Signals
ProfitablePositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 13 filings

Trend over 10 financial years

20252024202320222021
Income statement
Revenue3,6 Md €3,6 Md €2,6 Md €2,9 Md €3,3 Md €
EBITDA1,8 Md €1,8 Md €975,8 M €1,2 Md €1,6 Md €
Operating result135,6 M €-9,2 M €-751,6 M €-712,3 M €-590,6 M €
Net result113,8 M €8,5 M €-676,9 M €-519,5 M €-510,4 M €
Balance sheet
Equity1,2 Md €1,1 Md €293,4 M €970,3 M €489,8 M €
Total assets7,2 Md €6,2 Md €5,1 Md €5,3 Md €6,4 Md €
Cash153,8 M €25,9 M €87,1 M €87,4 M €244,9 M €
Debts5,6 Md €4,7 Md €4,3 Md €3,8 Md €5,3 Md €
Other
Workforce1 395,2 ETP1 317,9 ETP1 269,4 ETP1 267,9 ETP1 235,1 ETP

Valuation

Indicative valuation

As an indication, this company is worth

more than 1.000 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 6 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Alistair HENRY
Directorsince 01/07/2024
Denelle J. WAYNICK JOHNSON
Directorsince 01/04/2023
Sandrine DUFOUR
Directorsince 28/09/2020
Jean-Luc FLEURIAL
Directorsince 12/12/2017Manager12/12/2017 → 2018 accountsended

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
William SILBEY
Director22/03/2019 → 2022 accounts
Dhavalkumar PATEL
Director12/12/2017 → 01/07/2024

Other companies at this address

Allée de la Recherche 60 1070 Anderlecht
CompanyCBE no.
Fondation Emmanuel Janssen● Active
0408.369.901
U C B● Active
0403.053.608
UCB Belgium● Active
0402.040.254
UCB Developed Brands● Active
1017.533.562
UCB Fipar● Active
0403.198.811
UCB PHARMA● Active
0403.096.168
UCB Pillar 2● Active
1011.675.752
UCB Ventures● Active
0667.816.096
UCB Ventures Belgium● Active
0668.388.891
UNITE TVA UCB● Active
0820.436.985

Full financial information

Source · NBB
202520242023202220212020
Type of accountFull modelFull modelFull modelFull modelFull modelFull model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date23/07/202603/07/202516/07/202421/07/202318/07/202230/04/2021
General meeting29/06/202630/06/202524/06/202426/06/202327/06/202227/04/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 13 filings
ModelClosingGeneral meetingFiledLanguageDocument
Full model31/12/202529/06/202623/07/2026FrenchPDF
Full model31/12/202430/06/202503/07/2025FrenchPDF
Full model31/12/202324/06/202416/07/2024FrenchPDF
Full model31/12/202226/06/202321/07/2023FrenchPDF
Full model31/12/202127/06/202218/07/2022FrenchPDF
Full model31/12/202027/04/202130/04/2021FrenchPDF
Full model31/12/201929/06/202022/07/2020FrenchPDF
Full model31/12/201824/06/201912/07/2019FrenchPDF
Full modelCorrection31/12/201725/06/201831/07/2018FrenchPDF
Full model31/12/201725/06/201829/06/2018FrenchPDF
Full model31/12/201626/06/201728/06/2017FrenchPDF
Full model31/12/201504/05/201613/06/2016FrenchPDF
Full model31/12/201429/06/201502/07/2015FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

more than 1.000 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 6 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Alistair HENRY
Directorsince 01/07/2024
Denelle J. WAYNICK JOHNSON
Directorsince 01/04/2023
Sandrine DUFOUR
Directorsince 28/09/2020
Jean-Luc FLEURIAL
Directorsince 12/12/2017Manager12/12/2017 → 2018 accountsended

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
William SILBEY
Director22/03/2019 → 2022 accounts
Dhavalkumar PATEL
Director12/12/2017 → 01/07/2024

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Other02/01/2026
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …)
    PDF
  • Mandates02/10/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Other11/06/2025
    DIVERS
    PDF
  • Other12/05/2025
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - DIVERS
    PDF
  • Other18/03/2025
    DIVERS
    PDF
  • Other02/01/2025
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …)
    PDF
  • Mandates18/07/2024
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates04/08/2023
    DEMISSIONS, NOMINATIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings10 filings
Mandates
Alistair HENRY
Denelle J. WAYNICK JOHNSON
Sandrine DUFOUR
Jean-Luc FLEURIAL
William SILBEY
Dhavalkumar PATEL
Anna Sessan RICHO
Detlef THIELGEN
Mark Daniel McDADE
Fabrice René Marcel ENDERLIN
20132014201520162017201820192020202120222023202420252026
UCB BIOPHARMA
Allée de la Recherche 60, 1070 Anderlecht
Director
Director
Director
Director
Director
Director
Manager
DirectorManager
Manager
Manager
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Allée de la Recherche 60, 1070 AnderlechtCurrent
accounts 2021 → 2025
Accounts 2025 · 2026-00320055

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
UCB BIOPHARMACurrent
accounts 2014 → 2025
Accounts 2025 · 2026-00320055

Events

  1. 2025
    Annual accounts 2025113,8 M €↑
  2. 2024
    Annual accounts 20248,5 M €↑
  3. 24/06/2024
    nominationAlistair Henry · administrateur
  4. 24/06/2024
    nominationMazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL · commissaire aux comptes
  5. 2023
    Annual accounts 2023-676,9 M €↓
  6. 01/04/2023
    nominationDenelle J. Waynick Johnson · administrateur
  7. 2022
    Annual accounts 2022-519,5 M €↓
  8. 15/07/2022
    apport
  9. 2021
    Annual accounts 2021-510,4 M €↓
  10. 2020
    Annual accounts 2020-225,3 M €↑
  11. 2019
    Annual accounts 2019-569,4 M €↑
  12. 2018
    Annual accounts 2018-827,9 M €↓
  13. 2015
    Annual accounts 2015-290,8 M €↓
  14. 2014
    Annual accounts 20149,6 M €
  15. 24/12/2013
    IncorporationPrivate limited company